Neuroblastoma Drugs Market By Type (Chemotherapy, Immunotherapy, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Online, Offline): Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

The neuroblastoma drugs market was valued for $0.7 billion in 2022 and is estimated to reach $1.3 billion by 2032, exhibiting a CAGR of 6.2% from 2023 to 2032. Neuroblastoma is a type of cancer that primarily affects young children, typically arising in the adrenal glands, which are located on top of the kidneys. It is the most diagnosed disease in children under five, with most cases appearing in infants. This cancer originates from immature nerve cells, called neuroblasts, which are part of the sympathetic nervous system responsible for the "fight or flight" response.

Neuroblastoma varies widely in its behavior, ranging from spontaneous regression or maturation to aggressive, rapidly spreading forms. Symptoms of neuroblastoma can vary based on the location and size of the tumor but may include abdominal swelling, weight loss, irritability, fatigue, and changes in bowel habits. Neuroblastoma drugs are designed to target and inhibit the growth of cancerous neuroblastoma cells, either by directly attacking the cancer cells or by modulating the biological pathways involved in tumor development. The treatment approach for neuroblastoma often involves a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and other targeted therapies.

The neuroblastoma drugs market is driven by a rise in incidences of neuroblastoma, advancements in R&D activities, and growth in awareness of neuroblastoma. The increasing incidences and prevalence of neuroblastoma, particularly among pediatric populations, is a pivotal factor driving the growth of the neuroblastoma drugs market. For instance, according to the National Center for Biotechnology and Information (NCBI) in 2023, the annual incidence of neuroblastoma in the U.S. was approximately 650 cases, i.e., 10.2 per million children. Thus, the growing prevalence of neuroblastoma led to an urgent need for effective and targeted drug therapies which contribute toward the market growth.

Consequently, pharmaceutical companies and research institutions are compelled to intensify their efforts in drug development, clinical trials, and collaborative research initiatives to address this rising health concern. The market's response to the increasing disease burden emphasizes the importance of advancing innovative treatments to improve outcomes and quality of life for individuals affected by neuroblastoma. In addition, the pharmaceutical industry has been witnessing significant investments in oncology research and drug development, thereby boosting the market growth. Neuroblastoma, as a subset of pediatric oncology, benefits from this broader trend, with increased funding and resources allocated to discovering and developing novel drugs. For instance, the National Cancer Institute (NCI) has made substantial investments in basic research, leading to the development of dinutuximab, a treatment for neuroblastoma.

However, the high cost of neuroblastoma treatment, and harmful side effects associated with neuroblastoma drugs are the factors responsible for the impeding the growth of the neuroblastoma drug market. In contrast, rise in number of pipeline drugs for neuroblastoma provides lucrative opportunity to the market growth. In addition, the exploration of combination therapies involving different classes of drugs, such as traditional chemotherapeutics, targeted agents, and immunotherapies, offers opportunities for enhanced treatment efficacy.

The neuroblastoma drugs market is segmented into type, route of administration, distribution channel, and region. By type, the market is classified into chemotherapy, immunotherapy, and others. By route of administration, the market is segregated into oral and injectable. By distribution channel, the market is classified into online and offline. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). Major key players that operate in the neuroblastoma drugs market are Recordati Group,, AstraZeneca plc, Bristol-Myers Squibb Company, Cellectar Biosciences, Inc., Eli Lilly and Company, MacroGenics Inc, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Y-mabs Therapeutics, Inc. Key players operating in the market have adopted agreement, acquisition, partnership, and product approval as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neuroblastoma drugs market analysis from 2022 to 2032 to identify the prevailing neuroblastoma drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the neuroblastoma drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global neuroblastoma drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

Chemotherapy
Immunotherapy
Others

By Route of Administration

Oral
Injectable

By Distribution Channel

Online
Offline

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

AstraZeneca plc
Bristol-Myers Squibb Company
Cellectar Biosciences, Inc.
Eli Lilly and Company
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corporation
Y-mabs Therapeutics, Inc.
Recordati Group
MacroGenics Inc.

Product Code: A172697

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of neuroblastoma
  - 3.4.1.2. Growth in awareness & initiatives taken by the government for neuroblastoma
  - 3.4.1.3. Rise in R&D activities
- 3.4.2. Restraints
  - 3.4.2.1. Adverse effects and safety concerns
- 3.4.3. Opportunities
  - 3.4.3.1. Growth opportunities in emerging markets
  - 3.4.3.2. Rise in number of pipeline products

CHAPTER 4: NEUROBLASTOMA DRUGS MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Chemotherapy
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Immunotherapy
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Oral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Injectable
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Online
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Offline
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country

CHAPTER 7: NEUROBLASTOMA DRUGS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Route of Administration
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Type
  - 7.2.5.1.2. Market size and forecast, by Route of Administration
  - 7.2.5.1.3. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Type
  - 7.2.5.2.2. Market size and forecast, by Route of Administration
  - 7.2.5.2.3. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Type
  - 7.2.5.3.2. Market size and forecast, by Route of Administration
  - 7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Route of Administration
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Type
  - 7.3.5.1.2. Market size and forecast, by Route of Administration
  - 7.3.5.1.3. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Type
  - 7.3.5.2.2. Market size and forecast, by Route of Administration
  - 7.3.5.2.3. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Type
  - 7.3.5.3.2. Market size and forecast, by Route of Administration
  - 7.3.5.3.3. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Type
  - 7.3.5.4.2. Market size and forecast, by Route of Administration
  - 7.3.5.4.3. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Type
  - 7.3.5.5.2. Market size and forecast, by Route of Administration
  - 7.3.5.5.3. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Type
  - 7.3.5.6.2. Market size and forecast, by Route of Administration
  - 7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Route of Administration
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Type
  - 7.4.5.1.2. Market size and forecast, by Route of Administration
  - 7.4.5.1.3. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Type
  - 7.4.5.2.2. Market size and forecast, by Route of Administration
  - 7.4.5.2.3. Market size and forecast, by Distribution Channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Type
  - 7.4.5.3.2. Market size and forecast, by Route of Administration
  - 7.4.5.3.3. Market size and forecast, by Distribution Channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Type
  - 7.4.5.4.2. Market size and forecast, by Route of Administration
  - 7.4.5.4.3. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Type
  - 7.4.5.5.2. Market size and forecast, by Route of Administration
  - 7.4.5.5.3. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Type
  - 7.4.5.6.2. Market size and forecast, by Route of Administration
  - 7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Route of Administration
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Type
  - 7.5.5.1.2. Market size and forecast, by Route of Administration
  - 7.5.5.1.3. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Type
  - 7.5.5.2.2. Market size and forecast, by Route of Administration
  - 7.5.5.2.3. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Type
  - 7.5.5.3.2. Market size and forecast, by Route of Administration
  - 7.5.5.3.3. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Type
  - 7.5.5.4.2. Market size and forecast, by Route of Administration
  - 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Recordati Group
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. AstraZeneca plc
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Bristol-Myers Squibb Company
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Cellectar Biosciences, Inc.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
9.5. Eli Lilly and Company
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. MacroGenics Inc.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Pfizer Inc.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Teva Pharmaceutical Industries Ltd.
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. United Therapeutics Corporation
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Y-mabs Therapeutics, Inc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments